Siraj K Ahmed, MD
Pulmonary Disease · Manteca
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 3
- Since medical school
- 39 years
- Graduated 1987
Offices
3 locations · San Joaquin Critical Care Medical Group, Inc. · 9 clinicians in this group
Hospitals listed: Doctors Hospital of Manteca · St Joseph'S Medical Center of Stockton · Sutter Tracy Community Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Ahmed’s office to ask if they take your plan before you enroll.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Doctors Hospital of MantecaManteca, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency departmentPart of Tenet Healthcare, which runs 77 hospitals in 12 statesPatients rate it 2 of 5 · 55% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.165, Oct 2024 – Sep 2025
- St Joseph'S Medical Center of StocktonStockton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 3 of 5 · 67% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.08, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.34, Oct 2024 – Sep 2025
- Sutter Tracy Community HospitalTracy, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 71% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
See every measure and the patient survey for Doctors Hospital of Manteca
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 2 the same, 0 worse of 2 measures. Readmissions: 0 better, 4 the same, 2 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.165 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.01 (0 to 2.09) · 230 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.96 (0.49 to 1.42) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 30 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.5 · 110 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 172 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.7 · 81 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.5 · 700 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.33 (0.1 to 0.56) · 1,428 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.05 to 0.47) · 1,462 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.82 (1.24 to 6.39) · 137 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.28 (0.57 to 4) · 130 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.75 (0.23 to 3.28) · 58 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.41 (0 to 1.49) · 1,152 cases | No different | Jul 2022 – Jun 2024 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.4 · 173 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 67.3 · 110 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 60 · 183 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.4 · 250 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.8 · 48 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.2 to 16.8) · 379 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.5) · 52 cases | No different | Jan 2024 – Dec 2024 |
What patients said (339 patients answered, 15% of those asked)
| Cleanliness | 3 |
| Nurse communication | 1 |
| Doctor communication | 1 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 2 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 69% |
| Doctors "always" communicated well | 68% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 81% |
| Yes, staff "did" give patients information about help after discharge | 77% |
| Doctors "always" explained things so they could understand | 62% |
| Doctors "always" listened carefully | 65% |
| Doctors "always" treated them with courtesy and respect | 76% |
| Patients who gave a rating of "9" or "10" (high) | 56% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 62% |
| Nurses "always" listened carefully | 65% |
| Nurses "always" treated them with courtesy and respect | 79% |
| "Always" quiet at night | 39% |
| "YES", patients would definitely recommend the hospital | 55% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
See every measure and the patient survey for St Joseph'S Medical Center of Stockton
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 4 the same, 0 worse of 6 measures. Readmissions: 0 better, 6 the same, 2 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.08 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.34 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.51 (0.54 to 2.47) · 1,424 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.06 (0.78 to 1.33) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.22 (98.08 to 180.36) · 105 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 127 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 98 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.9 · 257 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.2 · 447 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 18.4 · 405 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9 · 337 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 3,812 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.29 (0.09 to 0.49) · 6,528 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,304 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.48 (1.49 to 5.48) · 1,467 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.27 (0 to 2.79) · 464 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.22 (0.81 to 3.64) · 1,404 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.16 (1.3 to 13.02) · 455 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.22 (1.5 to 8.93) · 456 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.24 (0.78 to 3.71) · 262 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.03 (0.53 to 1.53) · 6,521 cases | No different | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.537 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.486 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.646 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 484 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.9 · 878 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 22.2 · 265 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 17.1 · 493 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 407 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.3 · 615 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 14.1 · 184 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.4 · 248 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.6 to 17.6) · 164 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 290 cases | No different | Jan 2024 – Dec 2024 |
What patients said (541 patients answered, 14% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 64% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 41% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 51% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
See every measure and the patient survey for Sutter Tracy Community Hospital
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 1 better, 4 the same, 0 worse of 5 measures. Readmissions: 2 better, 5 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.28 (0.21 to 2.34) · 363 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.41 to 1.26) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 9.3 · 35 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.6 · 130 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.3 · 156 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 14.6 · 51 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 835 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.42) · 1,800 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.46) · 1,820 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.09 (0.6 to 5.57) · 291 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.51 (0 to 3.16) · 138 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.19 (0.51 to 3.87) · 274 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.77 (0 to 17.04) · 145 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.93 (0.72 to 9.15) · 133 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.72 (0.21 to 3.24) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.34 (0 to 1.34) · 1,481 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 26 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.981 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.796 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 18.8 · 194 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -47.9 · 145 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -5.1 · 154 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 186 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.8 · 42 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.3 to 16.7) · 504 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.7 to 1.5) · 104 cases | No different | Jan 2024 – Dec 2024 |
What patients said (443 patients answered, 16% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 77% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 77% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 71% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$466,210
Medicare paid this office $466,210 for 521 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Hyperbaric oxygen under pressure, full body chamber, per 30 minute interval | 25 | $251,707 | $155 |
| Critical care, first 30-74 minutes | 185 | $40,913 | $156 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 133 | $38,955 | $83 |
| Management of oxygen chamber therapy | 25 | $34,197 | $81 |
| Return visit (30+ min) | 136 | $18,877 | $92 |
See all 19 services
| Hyperbaric oxygen under pressure, full body chamber, per 30 minute interval | 25 | $251,707 | $155 |
| Critical care, first 30-74 minutes | 185 | $40,913 | $156 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 133 | $38,955 | $83 |
| Management of oxygen chamber therapy | 25 | $34,197 | $81 |
| Return visit (30+ min) | 136 | $18,877 | $92 |
| Sleep study including heart rate, breathing, and sleep time | 57 | $16,083 | $102 |
| New patient visit (45+ min) | 107 | $12,518 | $117 |
| Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | 180 | $11,078 | $35 |
| Detection test by immunoassay with direct visual observation for influenza virus | 171 | $9,505 | $16 |
| Short return visit (20+ min) | 67 | $5,158 | $61 |
| Test to examine how well the lungs exchange gases | 115 | $4,908 | $41 |
| Test to determine lung volumes using sensors | 115 | $4,738 | $40 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 126 | $3,692 | $27 |
| Test for exercise-induced lung stress | 117 | $2,859 | $23 |
| Manual attempt to restore blood circulation and breathing | 11 | $1,684 | $140 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 13 | $1,364 | $97 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 12 | $1,257 | $105 |
| Face-to-face behavioral counseling for obesity, 15 minutes | 40 | $1,061 | $23 |
| New patient visit (30+ min) | 14 | $1,060 | $76 |
Procedures Medicare counted
| Pacemaker insertion or repair | 1-10 | None |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Irrigation and suction of lung airways to obtain cells using an endoscope | 22 | 23 | 23 | 21 | – | 14 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 13 | 22 | 34 | – | 17 | 12 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 20 | 18 | 21 | – | 16 | – |
| Diagnostic exam of lung airway using an endoscope | – | – | – | – | 22 | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
521 Original Medicare patients in 2024. Average age 75 · Under 65 11% · 85 and older 15% · Women 51% · Also on Medicaid 53% · Health risk score 2.85. Above the middle of the specialty; the typical pulmonary disease clinician is at 2.13.
Conditions among them: High blood pressure 75% · Diabetes 56% · Coronary heart disease 53% · Heart failure 53% · Chronic kidney disease 52% · COPD 45% · Atrial fibrillation 40% · Depression 31% · Dementia 19% · Stroke 17% · Cancer 16%.
The office billed $1,697,192, Medicare allowed $589,169 and paid $466,210; for 4,933 services of 40 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 521 | 4,933 | 75 | 2.85 | $1,697,192 | $466,210 |
| 2023 | 515 | 4,070 | 75 | 2.77 | $1,558,671 | $423,694 |
| 2022 | 561 | 7,769 | 72 | 2.90 | $2,495,956 | $754,083 |
| 2021 | 698 | 8,794 | 72 | 2.96 | $2,440,619 | $906,469 |
| 2020 | 738 | 6,164 | 72 | 3.25 | $1,422,165 | $522,500 |
| 2019 | 655 | 3,562 | 72 | 3.26 | $895,580 | $324,446 |
| 2018 | 562 | 3,594 | 71 | 3.03 | $857,866 | $304,013 |
| 2017 | 222 | 1,024 | 72 | 2.12 | $379,238 | $101,816 |
| 2016 | 623 | 4,130 | 70 | 2.00 | $1,187,641 | $268,678 |
| 2015 | 543 | 2,796 | 70 | 1.83 | $862,704 | $180,654 |
| 2014 | 540 | 2,854 | 69 | 1.99 | $1,016,318 | $235,669 |
| 2013 | 691 | 4,405 | 70 | 2.00 | $1,452,803 | $348,826 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 25 services
| Hyperbaric oxygen under pressure, full body chamber, per 30 minute interval | 19 | $184,846 | $146 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 185 | $66,026 | $94 |
| Critical care, first 30-74 minutes | 177 | $52,921 | $167 |
| Management of oxygen chamber therapy | 19 | $26,646 | $83 |
| Sleep study including heart rate, breathing, and sleep time | 44 | $14,804 | $125 |
| Return visit (30+ min) | 79 | $13,985 | $95 |
| New patient visit (60+ min) | 44 | $7,806 | $177 |
| Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | 125 | $7,686 | $35 |
| New patient visit (45+ min) | 48 | $6,388 | $133 |
| Test to examine how well the lungs exchange gases | 119 | $5,746 | $47 |
| Test to determine lung volumes using sensors | 119 | $5,429 | $45 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 139 | $5,242 | $29 |
| Short return visit (20+ min) | 42 | $3,675 | $73 |
| Test for exercise-induced lung stress | 118 | $3,202 | $26 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 51 | $3,168 | $50 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 24 | $2,482 | $103 |
| Diagnostic exam of lung airway using an endoscope | 22 | $2,258 | $103 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 16 | $1,747 | $103 |
| Manual attempt to restore blood circulation and breathing | 12 | $1,716 | $143 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $1,659 | $138 |
| Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 16 | $1,176 | $74 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 15 | $917 | $57 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $882 | $63 |
| Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within | 15 | $368 | $25 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 12 | $81 | $7 |
2022: 20 services
| Hyperbaric oxygen under pressure, full body chamber, per 30 minute interval | 24 | $355,508 | $153 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 161 | $124,271 | $57 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 287 | $97,337 | $82 |
| Management of oxygen chamber therapy | 24 | $51,119 | $87 |
| Critical care, first 30-74 minutes | 94 | $45,554 | $174 |
| Follow-up inpatient or observation ventilation assistance and management | 29 | $10,788 | $53 |
| Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 94 | $10,519 | $74 |
| New patient visit (60+ min) | 62 | $10,402 | $168 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 60 | $8,966 | $149 |
| Return visit (30+ min) | 56 | $8,898 | $100 |
| Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | 88 | $5,097 | $35 |
| Test to examine how well the lungs exchange gases | 62 | $2,760 | $42 |
| Test to determine lung volumes using sensors | 61 | $2,523 | $39 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 63 | $2,248 | $28 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 20 | $2,165 | $103 |
| Test for exercise-induced lung stress | 75 | $1,891 | $23 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 15 | $1,170 | $51 |
| Short return visit (20+ min) | 15 | $1,065 | $67 |
| Evaluation of use of breathing device | 16 | $274 | $14 |
| Test for exercise-induced lung stress | 11 | $163 | $15 |
2021: 19 services
| Hyperbaric oxygen under pressure, full body chamber, per 30 minute interval | 22 | $374,687 | $143 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 350 | $146,231 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 201 | $137,164 | $58 |
| Critical care, first 30-74 minutes | 289 | $117,674 | $174 |
| Management of oxygen chamber therapy | 22 | $59,892 | $89 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 192 | $32,950 | $161 |
| New patient visit (45+ min) | 53 | $7,127 | $134 |
| Short return visit (20+ min) | 57 | $6,655 | $68 |
| Manual attempt to restore blood circulation and breathing | 29 | $4,156 | $143 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 34 | $3,823 | $112 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 21 | $2,365 | $103 |
| Return visit (30+ min) | 15 | $1,674 | $105 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 21 | $1,439 | $69 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 30 | $1,268 | $40 |
| Test to examine how well the lungs exchange gases | 24 | $1,223 | $51 |
| Critical care, each additional 30 minutes | 14 | $1,162 | $83 |
| Test to determine lung volumes using sensors | 24 | $1,118 | $47 |
| Test for exercise-induced lung stress | 34 | $978 | $27 |
| Test for exercise-induced lung stress | 11 | $223 | $19 |
2020: 14 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 210 | $189,735 | $59 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 341 | $139,736 | $85 |
| Critical care, first 30-74 minutes | 344 | $121,322 | $179 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 242 | $44,021 | $165 |
| Short return visit (20+ min) | 47 | $5,015 | $58 |
| New patient visit (45+ min) | 34 | $4,216 | $124 |
| Manual attempt to restore blood circulation and breathing | 19 | $3,225 | $154 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 21 | $2,573 | $117 |
| Critical care, each additional 30 minutes | 26 | $2,556 | $91 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 22 | $2,428 | $106 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 17 | $1,266 | $70 |
| Return visit (30+ min) | 16 | $1,162 | $68 |
| Test to measure expiratory airflow and volume | 36 | $918 | $26 |
| Test for exercise-induced lung stress | 22 | $621 | $28 |
2019: 17 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 307 | $141,317 | $84 |
| Critical care, first 30-74 minutes | 215 | $66,508 | $175 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 90 | $49,727 | $59 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 197 | $34,906 | $162 |
| Return visit (30+ min) | 45 | $5,583 | $86 |
| Critical care, each additional 30 minutes | 55 | $5,088 | $88 |
| New patient visit (45+ min) | 27 | $3,555 | $132 |
| Short return visit (20+ min) | 34 | $2,538 | $50 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 20 | $2,308 | $105 |
| Manual attempt to restore blood circulation and breathing | 14 | $2,266 | $151 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 13 | $1,478 | $114 |
| Hospital discharge day management, 30 minutes or less | 23 | $1,363 | $59 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 20 | $1,307 | $65 |
| Test for exercise-induced lung stress | 17 | $337 | $19 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 15 | $181 | $11 |
| Test to determine lung volumes using sensors | 15 | $171 | $10 |
| Test to examine how well the lungs exchange gases | 15 | $127 | $7 |
2018: 19 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 229 | $99,839 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 167 | $69,044 | $59 |
| Critical care, first 30-74 minutes | 149 | $57,174 | $178 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 179 | $32,153 | $162 |
| Return visit (30+ min) | 65 | $7,594 | $84 |
| New patient visit (45+ min) | 55 | $6,888 | $125 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 54 | $6,338 | $106 |
| Short return visit (20+ min) | 59 | $5,610 | $55 |
| Critical care, each additional 30 minutes | 21 | $2,228 | $89 |
| Hospital discharge day management, 30 minutes or less | 34 | $2,202 | $60 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 16 | $1,815 | $113 |
| Test for exercise-induced lung stress | 61 | $1,700 | $27 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,544 | $110 |
| Aspiration of fluid from chest cavity | 14 | $1,241 | $73 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 11 | $867 | $79 |
| Test to determine lung volumes using sensors | 46 | $435 | $9 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 39 | $387 | $10 |
| Test to examine how well the lungs exchange gases | 46 | $324 | $7 |
| Test for exercise-induced lung stress | 15 | $262 | $17 |
2017: 17 services
| Critical care, first 30-74 minutes | 53 | $26,729 | $175 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 72 | $18,874 | $78 |
| New patient visit (60+ min) | 67 | $10,765 | $161 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 49 | $8,867 | $161 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 14 | $5,953 | $425 |
| Return visit (30+ min) | 51 | $5,823 | $84 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 36 | $3,740 | $96 |
| Sleep study including heart rate, breathing, and sleep time | 18 | $3,226 | $101 |
| Short return visit (20+ min) | 34 | $2,732 | $59 |
| Long return visit (40+ min) | 14 | $1,515 | $108 |
| New patient visit (45+ min) | 13 | $1,104 | $85 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 11 | $1,073 | $98 |
| Pulmonary exercise testing | 47 | $958 | $20 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 41 | $412 | $10 |
| Test to determine lung volumes using sensors | 38 | $359 | $9 |
| Test to examine how well the lungs exchange gases | 37 | $258 | $7 |
| Exam of lung airways using an endoscope | 12 | $30 | $2 |
2016: 29 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 149 | $54,071 | $78 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 61 | $28,778 | $472 |
| Short return visit (20+ min) | 260 | $26,898 | $48 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 111 | $20,098 | $150 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 50 | $19,834 | $55 |
| Return visit (30+ min) | 156 | $16,533 | $71 |
| Sleep study in sleep lab (6 years or older) | 35 | $16,069 | $459 |
| New patient visit (60+ min) | 74 | $9,959 | $135 |
| Critical care, first 30-74 minutes | 11 | $8,019 | $167 |
| Pulmonary exercise testing | 165 | $7,468 | $41 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 168 | $7,297 | $43 |
| Test to examine how well the lungs exchange gases | 168 | $6,570 | $39 |
| Test to determine lung volumes using sensors | 165 | $6,263 | $38 |
| Test to measure rate of airflow | 164 | $5,450 | $28 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 42 | $3,724 | $87 |
| Home sleep test (hst) with type iv portable monitor, unattended; minimum of 3 channels | 26 | $3,309 | $123 |
| Hospital discharge day management, more than 30 minutes | 32 | $3,169 | $81 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 33 | $3,090 | $88 |
| Sleep study in sleep lab (6 years or older) | 34 | $2,769 | $81 |
| Evaluation of use of breathing device | 179 | $2,556 | $12 |
| Long return visit (40+ min) | 24 | $2,304 | $96 |
| New patient visit (45+ min) | 18 | $1,941 | $108 |
| Short return visit | 41 | $1,310 | $28 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 120 | $1,050 | $9 |
| Test to determine lung volumes using sensors | 118 | $1,000 | $8 |
| Test to examine how well the lungs exchange gases | 119 | $750 | $6 |
| Injection of drug or substance under skin or into muscle | 23 | $578 | $17 |
| Injection, methylprednisolone acetate, 40 mg | 20 | $65 | None |
| Injection, ceftriaxone sodium, per 250 mg | 14 | $15 | None |
2015: 26 services
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 60 | $26,736 | $446 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 107 | $23,349 | $77 |
| Short return visit (20+ min) | 229 | $22,932 | $47 |
| Sleep study in sleep lab (6 years or older) | 37 | $16,368 | $442 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 99 | $14,975 | $147 |
| Return visit (30+ min) | 96 | $8,890 | $67 |
| New patient visit (60+ min) | 63 | $8,299 | $132 |
| Hospital discharge day management, more than 30 minutes | 78 | $6,438 | $79 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 142 | $6,237 | $43 |
| Pulmonary exercise testing | 131 | $5,661 | $40 |
| Test to examine how well the lungs exchange gases | 144 | $5,584 | $38 |
| Test to determine lung volumes using sensors | 143 | $5,388 | $37 |
| Test to measure rate of airflow | 106 | $3,776 | $27 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 23 | $2,323 | $97 |
| Sleep study in sleep lab (6 years or older) | 26 | $2,131 | $82 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 23 | $2,092 | $91 |
| Evaluation of use of breathing device | 152 | $2,072 | $11 |
| Short return visit | 52 | $1,711 | $29 |
| Long return visit (40+ min) | 16 | $1,706 | $107 |
| Home sleep test (hst) with type iv portable monitor, unattended; minimum of 3 channels | 12 | $1,699 | $131 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 13 | $1,110 | $85 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 99 | $944 | $9 |
| Test to determine lung volumes using sensors | 99 | $907 | $9 |
| Test to examine how well the lungs exchange gases | 99 | $666 | $7 |
| Injection of drug or substance under skin or into muscle | 19 | $568 | $17 |
| Injection, methylprednisolone acetate, 40 mg | 18 | $68 | None |
2014: 26 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 172 | $42,699 | $78 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 69 | $31,971 | $463 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 166 | $25,867 | $148 |
| Sleep study in sleep lab (6 years or older) | 49 | $22,634 | $444 |
| Short return visit (20+ min) | 200 | $19,185 | $50 |
| Return visit (30+ min) | 170 | $16,424 | $70 |
| Critical care, first 30-74 minutes | 30 | $16,259 | $169 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 39 | $11,855 | $54 |
| New patient visit (60+ min) | 54 | $8,221 | $152 |
| Hospital discharge day management, more than 30 minutes | 74 | $6,391 | $81 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 87 | $3,609 | $41 |
| Test to examine how well the lungs exchange gases | 90 | $3,461 | $38 |
| Test to determine lung volumes using sensors | 88 | $3,290 | $37 |
| Pulmonary exercise testing | 67 | $2,902 | $40 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 30 | $2,757 | $89 |
| Test to measure rate of airflow | 73 | $2,195 | $27 |
| Sleep study in sleep lab (6 years or older) | 19 | $1,739 | $92 |
| New patient visit (45+ min) | 15 | $1,730 | $115 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 15 | $1,478 | $99 |
| Evaluation of use of breathing device | 96 | $1,271 | $12 |
| Long return visit (40+ min) | 11 | $1,186 | $108 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 61 | $615 | $10 |
| Short return visit | 16 | $614 | $32 |
| Test to determine lung volumes using sensors | 59 | $563 | $10 |
| Test to examine how well the lungs exchange gases | 61 | $431 | $7 |
| Exam of lung airways using an endoscope | 14 | $12 | $1 |
2013: 36 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 256 | $72,646 | $77 |
| Return visit (30+ min) | 298 | $68,600 | $72 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 234 | $38,669 | $144 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 80 | $37,480 | $469 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 69 | $23,951 | $53 |
| Sleep study in sleep lab (6 years or older) | 55 | $22,865 | $408 |
| Critical care, first 30-74 minutes | 28 | $13,401 | $165 |
| Hospital discharge day management, more than 30 minutes | 150 | $12,660 | $78 |
| New patient visit (60+ min) | 67 | $9,662 | $144 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 51 | $5,150 | $97 |
| Pulmonary exercise testing | 101 | $4,683 | $42 |
| Test to measure rate of airflow | 106 | $3,557 | $29 |
| Long return visit (40+ min) | 31 | $3,084 | $99 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 21 | $2,837 | $101 |
| Ultrasound of heart, follow-up | 34 | $2,630 | $73 |
| Short return visit (20+ min) | 51 | $2,595 | $48 |
| Test to examine how well the lungs exchange gases | 33 | $1,606 | $46 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 32 | $1,568 | $46 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 12 | $1,545 | $129 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 16 | $1,495 | $93 |
| Test to determine lung volumes using sensors | 24 | $1,111 | $44 |
| Sleep study in sleep lab (6 years or older) | 12 | $979 | $82 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 97 | $930 | $9 |
| Injection of drug or substance under skin or into muscle | 23 | $837 | $19 |
| Test to determine lung volumes using sensors | 85 | $794 | $9 |
| Evaluation of use of breathing device | 51 | $692 | $13 |
| Test to examine how well the lungs exchange gases | 99 | $692 | $7 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 47 | $611 | $13 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 31 | $482 | $15 |
| Administration of influenza virus vaccine | 17 | $403 | $24 |
| Smoking and tobacco use intensive counseling, more than 10 minutes | 18 | $295 | $11 |
| Exam of lung airways using an endoscope | 18 | $242 | $13 |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval) | 17 | $143 | $8 |
| Test to determine lung volumes using gas dilution or washout | 14 | $140 | $10 |
| Injection, methylprednisolone acetate, 40 mg | 20 | $52 | None |
| Injection, ceftriaxone sodium, per 250 mg | 15 | $26 | None |
Medicaid work
$301,454 in 2024
Medicaid paid $301,454 for 7,890 billed services this clinician did in 2024, up to 112 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Sleep study, unattended, simultaneous recording; heart rate, oxygen saturation, respiratory analysis (eg, by airflow or peripheral arterial tone), and sleep time | 436 | $65,465 |
| SARSCOV CORONAVIRUS AG IA | 1,072 | $42,081 |
| New patient visit (45+ min) | 432 | $33,135 |
| EVALUATION OF WHEEZING | 550 | $25,947 |
| Plethysmography for determination of lung volumes and, when performed, airway resistance | 450 | $24,113 |
| Diffusing capacity | 447 | $23,940 |
| Return visit (30+ min) | 527 | $22,158 |
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Influenza | 1,980 | $19,715 |
| PULMONARY STRESS TESTING | 479 | $15,953 |
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 127 | $12,965 |
| Short return visit (20+ min) | 253 | $6,818 |
| Handling and/or conveyance of specimen for transfer from physician office to laboratory | 998 | $4,089 |
| 2024 | 7,890 | 16 | 112 | $301,454 |
| 2023 | 4,986 | 17 | 105 | $229,531 |
| 2022 | 8,575 | 20 | 68 | $255,815 |
| 2021 | 6,639 | 11 | 48 | $206,005 |
| 2020 | 3,840 | 6 | 37 | $117,554 |
| 2019 | 2,219 | 3 | 30 | $66,873 |
| 2018 | 2,121 | 10 | 32 | $60,277 |
See the largest Medicaid services in earlier years
2023
| Sleep study, unattended, simultaneous recording; heart rate, oxygen saturation, respiratory analysis (eg, by airflow or peripheral arterial tone), and sleep time | 211 | $30,910 |
| EVALUATION OF WHEEZING | 614 | $27,058 |
| SARSCOV CORONAVIRUS AG IA | 629 | $23,320 |
| Plethysmography for determination of lung volumes and, when performed, airway resistance | 420 | $21,524 |
| Diffusing capacity | 418 | $21,428 |
| New patient visit (60+ min) | 190 | $17,315 |
| PULMONARY STRESS TESTING | 433 | $14,562 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 331 | $10,748 |
| Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 166 | $10,224 |
| Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique | 183 | $10,050 |
| Return visit (30+ min) | 254 | $10,040 |
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 101 | $9,703 |
2022
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 3,896 | $84,026 |
| Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 569 | $39,732 |
| Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 963 | $20,298 |
| SARSCOV CORONAVIRUS AG IA | 526 | $16,607 |
| EVALUATION OF WHEEZING | 373 | $15,649 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 484 | $12,157 |
| Diffusing capacity | 260 | $12,124 |
| Plethysmography for determination of lung volumes and, when performed, airway resistance | 259 | $12,077 |
| New patient visit (60+ min) | 129 | $10,535 |
| PULMONARY STRESS TESTING | 284 | $8,211 |
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) | 184 | $7,700 |
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 64 | $6,601 |
2021
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 3,965 | $96,744 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 1,520 | $43,979 |
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 371 | $36,791 |
| 1ST HOSP IP/OBS HIGH 75 | 118 | $6,535 |
| Short return visit (20+ min) | 200 | $4,492 |
| EVALUATION OF WHEEZING | 102 | $3,501 |
| Plethysmography for determination of lung volumes and, when performed, airway resistance | 87 | $3,330 |
| Diffusing capacity | 86 | $3,256 |
| New patient visit (45+ min) | 40 | $2,693 |
| SARSCOV CORONAVIRUS AG IA | 68 | $2,613 |
| PULMONARY STRESS TESTING | 82 | $2,070 |
2020
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 2,495 | $66,150 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 1,010 | $30,854 |
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 165 | $16,450 |
| Short return visit (20+ min) | 111 | $2,257 |
| New patient visit (45+ min) | 25 | $1,474 |
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 34 | $369 |
2019
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 1,308 | $44,282 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 882 | $19,391 |
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 29 | $3,200 |
2018
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 1,122 | $26,779 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 803 | $26,071 |
| New patient visit (45+ min) | 37 | $3,005 |
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 16 | $1,616 |
| Short return visit (20+ min) | 43 | $1,161 |
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 12 | $715 |
| EVALUATION OF WHEEZING | 25 | $322 |
| PULMONARY STRESS TESTING | 13 | $295 |
| Plethysmography for determination of lung volumes and, when performed, airway resistance | 25 | $188 |
| Diffusing capacity | 25 | $125 |
Drugs they prescribed that Part D paid
$670,747
Pharmacies billed $670,747 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,424) in 2024. At or below the middle of the specialty; the typical pulmonary disease clinician is at 0%.
628 generic and 796 brand-name prescriptions · $670,747 in drug cost · 85 antibiotic prescriptions to 69 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Trelegy Ellipta | 268 | $213,487 | $797 |
| Ofev | 12 | $155,439 | $12,953 |
| Prolastin C | 12 | $87,979 | $7,332 |
| Breztri Aerosphere | 49 | $42,765 | $873 |
| Anoro Ellipta | 29 | $15,695 | $541 |
See all 23 drugs
| Trelegy Ellipta | 268 | $213,487 | $797 |
| Ofev | 12 | $155,439 | $12,953 |
| Prolastin C | 12 | $87,979 | $7,332 |
| Breztri Aerosphere | 49 | $42,765 | $873 |
| Anoro Ellipta | 29 | $15,695 | $541 |
| Symbicort | 57 | $14,988 | $263 |
| Budesonide-Formoterol | 53 | $14,180 | $268 |
| Combivent Respimat | 30 | $13,912 | $464 |
| Spiriva Respimat | 20 | $13,723 | $686 |
| Breyna | 67 | $13,059 | $195 |
| Albuterol Sulfate Hfa | 341 | $9,207 | $27 |
| Breo Ellipta | 18 | $7,901 | $439 |
| Fluticasone Propionate Hfa | 21 | $4,882 | $232 |
| Wixela Inhub | 22 | $2,684 | $122 |
| Fluticasone-Salmeterol | 20 | $1,786 | $89 |
| Ventolin Hfa | 24 | $1,688 | $70 |
| Montelukast | 61 | $822 | $13 |
| Roflumilast | 20 | $785 | $39 |
| Methylprednisolone | 55 | $354 | $6 |
| Prednisone | 45 | $197 | $4 |
| Doxycycline Hyclate | 30 | $182 | $6 |
| Azithromycin | 34 | $112 | $3 |
| Levofloxacin | 12 | $44 | $4 |
Year by year
| 2024 | 1,424 | 302 | 0% (0) | 56% | $670,747 |
| 2023 | 1,107 | 225 | 0% (0) | 72% | $537,052 |
| 2022 | 663 | 146 | None | 73% | $250,854 |
| 2021 | 403 | 96 | 0% (0) | 77% | $135,342 |
| 2020 | 333 | 69 | None | 78% | $234,674 |
| 2019 | 294 | 62 | 0% (0) | 68% | $213,267 |
| 2018 | 253 | 63 | 0% (0) | 60% | $63,760 |
| 2017 | 467 | 123 | 0% (0) | 69% | $229,170 |
| 2016 | 1,297 | 182 | 1% (15) | 53% | $398,532 |
| 2015 | 1,432 | 196 | 2% (31) | 50% | $331,537 |
| 2014 | 1,318 | 197 | 3% (35) | 52% | $297,857 |
| 2013 | 1,757 | 226 | 4% (76) | 51% | $298,650 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 17 drugs
| Trelegy Ellipta | 316 | $233,187 | $738 |
| Symbicort | 107 | $47,773 | $446 |
| Breztri Aerosphere | 47 | $34,514 | $734 |
| Anoro Ellipta | 38 | $17,767 | $468 |
| Spiriva Respimat | 27 | $13,948 | $517 |
| Combivent Respimat | 27 | $13,262 | $491 |
| Albuterol Sulfate Hfa | 176 | $6,219 | $35 |
| Roflumilast | 49 | $5,830 | $119 |
| Advair Diskus | 16 | $5,713 | $357 |
| Budesonide-Formoterol | 20 | $5,030 | $251 |
| Ventolin Hfa | 42 | $3,030 | $72 |
| Wixela Inhub | 18 | $1,993 | $111 |
| Doxycycline Hyclate | 30 | $685 | $23 |
| Prednisone | 30 | $554 | $18 |
| Montelukast | 23 | $327 | $14 |
| Methylprednisolone | 19 | $265 | $14 |
| Azithromycin | 13 | $110 | $8 |
2022: 11 drugs
| Trelegy Ellipta | 187 | $127,380 | $681 |
| Symbicort | 71 | $28,269 | $398 |
| Breztri Aerosphere | 37 | $25,398 | $686 |
| Advair Diskus | 19 | $6,865 | $361 |
| Spiriva Respimat | 11 | $5,507 | $501 |
| Albuterol Sulfate Hfa | 105 | $4,439 | $42 |
| Ventolin Hfa | 26 | $1,694 | $65 |
| Wixela Inhub | 11 | $1,612 | $147 |
| Prednisone | 45 | $498 | $11 |
| Montelukast | 20 | $332 | $17 |
| Fluticasone Propionate | 17 | $304 | $18 |
2021: 8 drugs
| Trelegy Ellipta | 76 | $51,519 | $678 |
| Symbicort | 76 | $31,268 | $411 |
| Spiriva Respimat | 26 | $12,683 | $488 |
| Breztri Aerosphere | 19 | $11,175 | $588 |
| Albuterol Sulfate Hfa | 51 | $1,949 | $38 |
| Ventolin Hfa | 22 | $1,256 | $57 |
| Montelukast | 19 | $296 | $16 |
| Prednisone | 17 | $149 | $9 |
2020: 10 drugs
| Prolastin C | 12 | $134,748 | $11,229 |
| Symbicort | 70 | $29,956 | $428 |
| Spiriva Respimat | 56 | $28,955 | $517 |
| Trelegy Ellipta | 26 | $15,301 | $589 |
| Advair Diskus | 14 | $4,915 | $351 |
| Ventolin Hfa | 20 | $1,258 | $63 |
| Albuterol Sulfate Hfa | 28 | $1,124 | $40 |
| Doxycycline Hyclate | 13 | $352 | $27 |
| Montelukast | 14 | $305 | $22 |
| Prednisone | 15 | $175 | $12 |
2019: 9 drugs
| Prolastin C | 13 | $138,911 | $10,685 |
| Spiriva Respimat | 36 | $18,354 | $510 |
| Symbicort | 41 | $17,155 | $418 |
| Advair Diskus | 31 | $12,913 | $417 |
| Trelegy Ellipta | 17 | $9,736 | $573 |
| Ventolin Hfa | 20 | $1,614 | $81 |
| Doxycycline Hyclate | 11 | $257 | $23 |
| Prednisone | 21 | $240 | $11 |
| Montelukast | 13 | $238 | $18 |
2018: 7 drugs
| Symbicort | 40 | $12,824 | $321 |
| Advair Diskus | 25 | $10,146 | $406 |
| Breo Ellipta | 12 | $4,236 | $353 |
| Ventolin Hfa | 13 | $817 | $63 |
| Montelukast | 25 | $623 | $25 |
| Doxycycline Hyclate | 12 | $189 | $16 |
| Prednisone | 14 | $161 | $11 |
2017: 9 drugs
| Breo Ellipta | 59 | $22,562 | $382 |
| Symbicort | 60 | $21,018 | $350 |
| Advair Diskus | 30 | $17,472 | $582 |
| Combivent Respimat | 31 | $14,317 | $462 |
| Spiriva Respimat | 27 | $9,828 | $364 |
| Ventolin Hfa | 34 | $2,312 | $68 |
| Proair Hfa | 17 | $1,074 | $63 |
| Prednisone | 26 | $349 | $13 |
| Montelukast | 12 | $314 | $26 |
2016: 39 drugs
| Xyrem | 14 | $173,267 | $12,376 |
| Symbicort | 126 | $44,482 | $353 |
| Combivent Respimat | 79 | $33,088 | $419 |
| Breo Ellipta | 88 | $30,378 | $345 |
| Advair Diskus | 53 | $28,675 | $541 |
| Nuvigil | 16 | $18,467 | $1,154 |
| Daliresp | 20 | $10,401 | $520 |
| Spiriva Respimat | 23 | $7,608 | $331 |
| Spiriva | 12 | $5,259 | $438 |
| Ventolin Hfa | 63 | $4,806 | $76 |
| Incruse Ellipta | 15 | $4,629 | $309 |
| Proair Hfa | 61 | $4,105 | $67 |
| Doxycycline Hyclate | 47 | $1,243 | $26 |
| Xopenex Hfa | 17 | $1,185 | $70 |
| Proventil Hfa | 13 | $920 | $71 |
| Prednisone | 59 | $681 | $12 |
| Enalapril Maleate | 22 | $547 | $25 |
| Metoprolol | 14 | $457 | $33 |
| Montelukast | 21 | $406 | $19 |
| Atorvastatin | 33 | $331 | $10 |
| Metformin | 33 | $294 | $9 |
| Methylprednisolone | 19 | $270 | $14 |
| Eszopiclone | 11 | $245 | $22 |
| Hydrocodone-Acetaminophen | 14 | $237 | $17 |
| Pentoxifylline | 12 | $228 | $19 |
| Amoxicillin-Clavulanate Potass | 18 | $211 | $12 |
| Potassium Chloride | 11 | $164 | $15 |
| Amlodipine Besylate | 24 | $149 | $6 |
| Ropinirole | 14 | $143 | $10 |
| Metoprolol | 19 | $139 | $7 |
| Fluticasone Propionate | 11 | $126 | $11 |
| Simvastatin | 14 | $112 | $8 |
| Triamterene-Hydrochlorothiazid | 12 | $101 | $8 |
| Glipizide | 12 | $91 | $8 |
| Azithromycin | 11 | $75 | $7 |
| Cephalexin | 13 | $72 | $6 |
| Lorazepam | 11 | $64 | $6 |
| Furosemide | 16 | $60 | $4 |
| Atenolol | 11 | $55 | $5 |
2015: 42 drugs
| Xyrem | 11 | $124,953 | $11,359 |
| Advair Diskus | 85 | $37,776 | $444 |
| Combivent Respimat | 88 | $29,017 | $330 |
| Nuvigil | 32 | $24,183 | $756 |
| Symbicort | 78 | $23,889 | $306 |
| Spiriva | 47 | $21,177 | $451 |
| Daliresp | 28 | $10,902 | $389 |
| Breo Ellipta | 25 | $8,453 | $338 |
| Proair Hfa | 121 | $7,691 | $64 |
| Tudorza Pressair | 17 | $7,313 | $430 |
| Chantix | 12 | $3,380 | $282 |
| Dymista | 16 | $2,655 | $166 |
| Doxycycline Hyclate | 43 | $1,377 | $32 |
| Ventolin Hfa | 14 | $1,212 | $87 |
| Prednisone | 58 | $603 | $10 |
| Valsartan | 15 | $485 | $32 |
| Eszopiclone | 16 | $442 | $28 |
| Enalapril Maleate | 19 | $428 | $23 |
| Theophylline Anhydrous | 11 | $415 | $38 |
| Hydrocodone-Acetaminophen | 31 | $376 | $12 |
| Atorvastatin | 35 | $349 | $10 |
| Potassium Chloride | 23 | $328 | $14 |
| Methylprednisolone | 17 | $308 | $18 |
| Azithromycin | 29 | $307 | $11 |
| Metoprolol | 16 | $271 | $17 |
| Metformin | 52 | $267 | $5 |
| Ropinirole | 21 | $255 | $12 |
| Levofloxacin | 17 | $240 | $14 |
| Quinapril | 17 | $231 | $14 |
| Amlodipine Besylate | 35 | $223 | $6 |
| Pentoxifylline | 12 | $184 | $15 |
| Furosemide | 31 | $162 | $5 |
| Simvastatin | 21 | $159 | $8 |
| Metoprolol | 22 | $134 | $6 |
| Warfarin | 18 | $133 | $7 |
| Glipizide Xl | 11 | $121 | $11 |
| Methimazole | 13 | $109 | $8 |
| Alendronate | 11 | $83 | $8 |
| Levothyroxine | 16 | $82 | $5 |
| Pantoprazole | 11 | $76 | $7 |
| Triamterene-Hydrochlorothiazid | 12 | $67 | $6 |
| Glipizide | 12 | $51 | $4 |
2014: 31 drugs
| Xyrem | 12 | $112,747 | $9,396 |
| Advair Diskus | 111 | $44,557 | $401 |
| Spiriva | 73 | $29,235 | $400 |
| Combivent Respimat | 60 | $20,061 | $334 |
| Symbicort | 66 | $19,779 | $300 |
| Nuvigil | 20 | $11,402 | $570 |
| Daliresp | 26 | $7,089 | $273 |
| Tudorza Pressair | 20 | $5,996 | $300 |
| Proair Hfa | 80 | $4,809 | $60 |
| Bystolic | 20 | $2,173 | $109 |
| Chantix | 11 | $2,145 | $195 |
| Prednisone | 51 | $616 | $12 |
| Hydrocodone-Acetaminophen | 32 | $455 | $14 |
| Theophylline Anhydrous | 17 | $446 | $26 |
| Azithromycin | 47 | $414 | $9 |
| Omeprazole | 17 | $406 | $24 |
| Atorvastatin | 20 | $355 | $18 |
| Quinapril | 11 | $312 | $28 |
| Methylprednisolone | 15 | $292 | $19 |
| Levofloxacin | 26 | $254 | $10 |
| Metformin | 38 | $230 | $6 |
| Pentoxifylline | 11 | $229 | $21 |
| Furosemide | 41 | $223 | $5 |
| Pantoprazole | 11 | $204 | $19 |
| Potassium Chloride | 12 | $166 | $14 |
| Levothyroxine | 16 | $144 | $9 |
| Enalapril Maleate | 11 | $119 | $11 |
| Glipizide Xl | 11 | $109 | $10 |
| Lisinopril | 18 | $106 | $6 |
| Simvastatin | 11 | $82 | $7 |
| Triamterene-Hydrochlorothiazid | 11 | $64 | $6 |
2013: 49 drugs
| Xyrem | 12 | $92,371 | $7,698 |
| Advair Diskus | 115 | $44,989 | $391 |
| Spiriva | 68 | $26,123 | $384 |
| Symbicort | 69 | $21,714 | $315 |
| Nuvigil | 26 | $11,781 | $453 |
| Combivent Respimat | 33 | $10,115 | $307 |
| Daliresp | 36 | $8,659 | $241 |
| Tudorza Pressair | 29 | $6,892 | $238 |
| Lunesta | 27 | $6,794 | $252 |
| Proair Hfa | 101 | $5,346 | $53 |
| Crestor | 16 | $3,757 | $235 |
| Combivent | 13 | $2,883 | $222 |
| Levemir Flexpen | 11 | $2,880 | $262 |
| Chantix | 11 | $2,170 | $197 |
| Montelukast | 28 | $2,124 | $76 |
| Bystolic | 12 | $1,972 | $164 |
| Amphetamine Salt Combo | 25 | $1,629 | $65 |
| Ventolin Hfa | 31 | $1,400 | $45 |
| Benicar | 11 | $1,126 | $102 |
| Azithromycin | 74 | $1,010 | $14 |
| Novolin N | 11 | $901 | $82 |
| Xopenex Hfa | 15 | $844 | $56 |
| Hydrocodone-Acetaminophen | 58 | $781 | $13 |
| Theophylline Anhydrous | 34 | $753 | $22 |
| Ropinirole | 17 | $684 | $40 |
| Levofloxacin | 52 | $674 | $13 |
| Atorvastatin | 26 | $670 | $26 |
| Clopidogrel | 14 | $565 | $40 |
| Methylprednisolone | 26 | $557 | $21 |
| Prednisone | 48 | $342 | $7 |
| Potassium Chloride | 23 | $324 | $14 |
| Simvastatin | 25 | $287 | $11 |
| Pentoxifylline | 12 | $264 | $22 |
| Furosemide | 56 | $262 | $5 |
| Famotidine | 19 | $213 | $11 |
| Amox Tr-Potassium Clavulanate | 11 | $212 | $19 |
| Amlodipine Besylate | 27 | $203 | $8 |
| Pramipexole Dihydrochloride | 13 | $193 | $15 |
| Metformin | 22 | $181 | $8 |
| Quinapril | 12 | $158 | $13 |
| Pantoprazole | 12 | $157 | $13 |
| Glipizide Xl | 12 | $139 | $12 |
| Levothyroxine | 15 | $119 | $8 |
| Carvedilol | 11 | $110 | $10 |
| Zolpidem | 15 | $107 | $7 |
| Enalapril Maleate | 12 | $102 | $9 |
| Triamterene-Hctz | 12 | $87 | $7 |
| Lisinopril | 13 | $73 | $6 |
| Fluconazole | 12 | $71 | $6 |
Money from drug and device companies
$1,595 in 2025
| 2025 | 20 | 74 | None | $1,595 |
| 2024 | 13 | 49 | None | $1,465 |
| 2023 | 14 | 74 | None | $1,781 |
| 2022 | 8 | 45 | None | $703 |
| 2021 | 8 | 28 | None | $406 |
| 2019 | 1 | 1 | None | $114 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Breztri | $305 | 9 payments
|
| Verona Pharma | Ohtuvayre | $220 | 8 payments
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $173 | 8 payments
|
| Grifols USA | Prolastin-C Liquid | $144 | 4 payments
|
| Bayer Healthcare Pharmaceuticals | Adempas | $144 | 3 payments
|
| Viatris Specialty | Yupelri | $115 | 5 payments
|
See all 59 published payments
| Viatris Specialty | Meals · 2025-12-08 | Yupelri | $20 |
| Amgen | Meals · 2025-12-03 | Tezspire | $19 |
| Verona Pharma | Meals · 2025-12-02 | Ohtuvayre | $31 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-20 | Breztri | $22 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-11-17 | Jascayd | $18 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-11-14 | Adempas | $15 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-13 | None | $36 |
| Grifols USA | Meals · 2025-11-13 | Prolastin-C Liquid | $55 |
| Amgen | Meals · 2025-11-06 | Tezspire | $19 |
| Viatris Specialty | Meals · 2025-11-05 | Yupelri | $25 |
| Itamar Medical | Meals · 2025-11-05 | Watchpatone | $25 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-10-20 | Jascayd | $14 |
| Lilly USA | Meals · 2025-10-17 | Zepbound | $17 |
| Grifols USA | Meals · 2025-10-15 | Prolastin-C Liquid | $15 |
| Amgen | Meals · 2025-10-14 | Tezspire | $23 |
| GlaxoSmithKline | Meals · 2025-10-13 | Trelegy Ellipta | $16 |
| Viatris Specialty | Meals · 2025-10-06 | Yupelri | $22 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-10-04 | Adempas | $117 |
| Resmed | Meals · 2025-09-30 | Airsense | $14 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-19 | Breztri | $25 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-09-04 | Ofev | $15 |
| GlaxoSmithKline | Meals · 2025-08-26 | Trelegy Ellipta | $24 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-23 | Tezspire | $28 |
| Verona Pharma | Meals · 2025-08-22 | Ohtuvayre | $30 |
| Viatris Specialty | Meals · 2025-08-20 | Yupelri | $22 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-08-18 | Adempas | $11 |
| Verona Pharma | Meals · 2025-08-14 | Ohtuvayre | $18 |
| Genzyme | Meals · 2025-08-13 | Dupixent | $37 |
| Grifols USA | Meals · 2025-08-13 | Prolastin-C Liquid | $41 |
| Actelion Pharmaceuticals US | Meals · 2025-08-05 | Opsumit | $21 |
| Viatris Specialty | Meals · 2025-07-17 | Yupelri | $26 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-07-09 | Ofev | $30 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-26 | Breztri | $26 |
| GlaxoSmithKline | Meals · 2025-06-18 | Nucala | $20 |
| Verona Pharma | Meals · 2025-06-17 | Ohtuvayre | $9 |
| Insmed | Meals · 2025-06-03 | Arikayce | $35 |
| Regeneron Healthcare Solutions | Meals · 2025-06-02 | Dupixent | $20 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-05-23 | Ofev | $29 |
| Verona Pharma | Meals · 2025-05-22 | Ohtuvayre | $108 |
| Fisher & Paykel Healthcare | Meals · 2025-05-21 | Fisher & Paykel Healthcare | $27 |
| Pulmonx | Meals · 2025-05-19 | Chartis Catheter | $19 |
| Jazz Pharmaceuticals | Meals · 2025-04-28 | Xywav | $29 |
| Verona Pharma | Meals · 2025-04-22 | Ohtuvayre | $12 |
| Edwards Lifesciences | Meals · 2025-04-08 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) | $26 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-04-02 | Ofev | $17 |
| Lilly USA | Meals · 2025-03-26 | Zepbound | $30 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-03-18 | Glassia | $17 |
| Grifols USA | Meals · 2025-03-18 | Prolastin-C Liquid | $33 |
| Verona Pharma | Meals · 2025-03-04 | Ohtuvayre | $5 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-22 | Breztri | $92 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-22 | Tezspire | $23 |
| Lilly USA | Meals · 2025-02-18 | Zepbound | $18 |
| Verona Pharma | Meals · 2025-02-17 | Ohtuvayre | $6 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-02-14 | Ofev | $31 |
| GlaxoSmithKline | Meals · 2025-02-10 | Nucala | $17 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-05 | Tezspire | $29 |
| Regeneron Healthcare Solutions | Meals · 2025-02-03 | Dupixent | $24 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-01-11 | Ofev | $18 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-10 | Airsupra | $24 |
See earlier years (2024, 2023, 2022, 2021, 2019)
2024: $1,465
| Regeneron Healthcare Solutions | Dupixent | $309 | 9 payments
|
| Itamar Medical | Watchpatone | $240 | 1 payment
|
| Genzyme | Dupixent | $163 | 3 payments
|
| Actelion Pharmaceuticals US | Opsumit | $142 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Tezspire | $142 | 6 payments
|
| Mylan Specialty L.P. | Yupelri | $139 | 6 payments
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $102 | 5 payments
|
| GlaxoSmithKline | Trelegy Ellipta | $59 | 3 payments
|
| Takeda Pharmaceuticals U.S.A. | Glassia | $57 | 2 payments
|
| Amgen | Tezspire | $41 | 2 payments
|
| Grifols USA | Prolastin-C Liquid | $28 | 1 payment
|
| Insmed | Arikayce | $24 | 1 payment
|
| Resmed | Airsense | $18 | 1 payment
|
2023: $1,781
| Regeneron Healthcare Solutions | Dupixent | $383 | 10 payments
|
| GlaxoSmithKline | Trelegy Ellipta | $351 | 21 payments
|
| AstraZeneca Pharmaceuticals LP | Breztri | $281 | 10 payments
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $146 | 7 payments
|
| Mylan Specialty L.P. | Yupelri | $132 | 5 payments
|
| Itamar Medical | Watchpatone | $116 | 1 payment
|
| Actelion Pharmaceuticals US | Opsumit | $89 | 3 payments
|
| Sanofi-Aventis U.S. | Dupixent | $80 | 1 payment
|
| Amgen | Tezspire | $51 | 3 payments
|
| Grifols USA | Prolastin-C Liquid | $51 | 3 payments
|
| Janssen Pharmaceuticals | Xarelto | $50 | 3 payments
|
| Idorsia Pharmaceuticals US | Quviviq | $28 | 2 payments
|
| Genzyme | Dupixent | $18 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $5 | 1 payment
|
2022: $703
| GlaxoSmithKline | Trelegy Ellipta | $221 | 14 payments
|
| AstraZeneca Pharmaceuticals LP | Breztri | $160 | 6 payments
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $101 | 4 payments
|
| Mylan Specialty L.P. | Yupelri | $78 | 4 payments
|
| Janssen Pharmaceuticals | Xarelto | $66 | 4 payments
|
| Regeneron Healthcare Solutions | Dupixent | $35 | 1 payment
|
| Grifols USA | Prolastin-C Liquid | $24 | 1 payment
|
| Actelion Pharmaceuticals US | Opsumit | $19 | 1 payment
|
2021: $406
| AstraZeneca Pharmaceuticals LP | Farxiga | $160 | 7 payments
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $111 | 3 payments
|
| Mylan Specialty L.P. | Yupelri | $30 | 2 payments
|
| Janssen Pharmaceuticals | Xarelto | $29 | 2 payments
|
| Gilead Sciences | None | $27 | 1 payment
|
| Vapotherm | Vapotherm | $20 | 1 payment
|
| Philips Electronics North America | (8874) Incourage | $16 | 1 payment
|
| Boston Scientific | General Pain Management | $14 | 1 payment
|
2019: $114
| Teva Pharmaceuticals USA | Cinqair | $114 | 1 payment
|
Professional record
- NPI
- 1265513121
- Licence
- IN 01041335A
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 1265513121
- Taxonomy
- Federal specialty code 207RP1001X (207RP1001X); Internal medicine (207R00000X)
- Mailing address
- 1112 North Main Street, Pmb 311, Manteca, CA, 95336
- NPI first listed
- 2006-10-18
- NPI last updated
- 2019-10-03
This is when the NPI record was last certified, not a medical board exam.